InMed CEO, Eric A. Adams, speaks with Shadd Dales of The Dales Report, and talks about whether the industry is ready for synthesized cannabinoids.
Read the article and watch the full video at The Dales Report.
What quality controls should be put in place to ensure consistency and purity of cannabinoids for CPG products?
Dr. Shane Johnson, GM of BayMedica, InMed’s subsidiary, answers these questions: What is the minimum GMP standard that consumers should expect? What quality controls should
August 18, 2023
